Physician profile
Mark Ryan Kauth
NPI 1568992014
$1,427.79
in general payments reported to CMS, 2019-2025
12 companies · $624 in 2025
The $624 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $219 · 2024: $473 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $725.27 | 2023-2025 | Avvigo Guidance System, Rotapro |
| Abbott Laboratories | $203.98 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Perclose Prostyle |
| Penumbra, INC. | $141.22 | 2024 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $114.91 | 2022-2024 | Brilinta |
| Abiomed | $93.06 | 2024-2025 | Impella |
| Pfizer INC. | $33.07 | 2024-2025 | |
| Medtronic, INC. | $24.43 | 2024 | Onyx Frontier |
| Novo Nordisk INC | $24.34 | 2023 | Ozempic |
| Teleflex LLC | $23.34 | 2022 | |
| Terumo Medical Corporation | $17.59 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.34 | 2024 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.24 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kauth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.